Repurposed drug may extend survival in aggressive ovarian cancer, trial shows
Relacorilant, typically used to treat Cushing’s syndrome, could improve outcomes in platinum-resistant cases
A drug originally used to treat a rare disease could extend the lives of patients with an aggressive form of ovarian cancer, according to a clinical trial.
Platinum-resistant ovarian cancer occurs when the disease progresses within six months of starting platinum-based chemotherapy. This form of chemotherapy is different from other types because it uses compounds that contain platinum to destroy cancer cells by preventing them from dividing.
Source: Theguardian.com
Original source: https://www.theguardian.com/society/2026/apr/10/drug-extend-survival-aggressive-ovarian-cancer-trial-relacorilant